AFFY Cash Flow Statement

Click line-items for a historical chart and %
Cash flows from operating activities
Net income (loss)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization 386K
Amortization of discount/premium on investments 6K
Stock-based compensation expense 3.35M
Gain on disposal of property and equipment 0
Changes in operating assets and liabilities:
Receivable from Takeda 17.49M
Income taxes receivable
Prepaid expenses and other current assets -228K
Other assets
Accounts payable 2.72M
Accrued liabilities -9.34M
Accrued clinical trial expenses -610K
Payable to Takeda
Deferred revenue
Long-term income tax liability
Other long-term liabilities
Net cash used in operating activities
Cash flows from investing activities
Purchases of property and equipment 0
Purchases of investments
Proceeds from sales of investments
Proceeds from maturities of investments 3.6M
Proceeds from sale of property and equipment 0
Net cash provided by (used in) investing activities
Cash flows from financing activities
Proceeds from issuance of common stock upon exercise of stock options 271K
Proceeds from issuance of common stock under employee stock purchase plan
Proceeds from common stock issued upon public offering, net of issuance cost
Repayment of UBS loan
Net cash provided by (used in) financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of the period 68.27M
Cash and cash equivalents at end of the period 46.62M

Entities mentioned with AFFY

View All Entities